EX-32.1 6 a06302024ex321.htm EX-32.1
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Werewolf Therapeutics, Inc. (the “Company”) for the period ended June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 8, 2024 | By: | /s/ Daniel J. Hicklin
|  | Daniel J. Hicklin, Ph.D.
|  | President and Chief Executive Officer (Principal Executive Officer)
Date: August 8, 2024 | By: | /s/ Timothy W. Trost
|  | Timothy W. Trost
|  | Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)

1